We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+37.79%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$2.62B
AUM Growth
+$630M
Cap. Flow
+$217M
Cap. Flow %
8.29%
Top 10 Hldgs %
54.13%
Holding
172
New
46
Increased
29
Reduced
19
Closed
33

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$64.1M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$36.1M
3
XLRN
Acceleron Pharma
XLRN
+$31.4M
4
PBYI icon
Puma Biotechnology
PBYI
+$17.7M
5
CBAY
Cymabay Therapeutics
CBAY
+$15.9M

Top Sells

Rank Stock Value
1
ARAV
Aravive, Inc. Common Stock
ARAV
+$42.4M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$36.7M
3
RDUS
Radius Health, Inc.
RDUS
+$29.2M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$20.9M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 98.22%
2 Industrials 0.33%
3 Consumer Staples 0.16%
4 Consumer Discretionary 0.07%
5 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXEL icon
101
Exelixis
EXEL
$14.1B
$1.12M 0.04%
46,361
– –
STLA icon
102
Stellantis
STLA
$19.8B
$1.11M 0.04%
62,000
-248
-0.4% -$3.43K
LNTH icon
103
Lantheus
LNTH
$6.58B
$957K 0.04%
53,763
– –
GRDX
104
GridAI Technologies Corp
GRDX
$28.7M
$907K 0.03%
2
– –
CNC icon
105
Centene
CNC
$32.1B
$748K 0.03%
15,452
– –
VYGR icon
106
Voyager Therapeutics
VYGR
$214M
$712K 0.03%
34,604
– –
RACE icon
107
Ferrari
RACE
$74.1B
$685K 0.03%
6,200
– –
TARA icon
108
Protara Therapeutics
TARA
$235M
$668K 0.03%
8,353
– –
INCY icon
109
Incyte
INCY
$26.3B
$656K 0.03%
5,619
– –
VNDA icon
110
Vanda Pharmaceuticals
VNDA
$329M
$649K 0.02%
36,232
– –
HSKA
111
DELISTED
Heska Corp
HSKA
$643K 0.02%
7,300
– –
ALGN icon
112
Align Technology
ALGN
$11.3B
$642K 0.02%
+3,448
New +$590K
KERX
113
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$592K 0.02%
+83,386
New +$600K
ONC
114
BeOne Medicines Ltd
ONC
$42.6B
$590K 0.02%
+5,700
New +$425K
ATRA icon
115
Atara Biotherapeutics
ATRA
$98.8M
$581K 0.02%
+1,404
New +$529K
PRAH
116
DELISTED
PRA Health Sciences, Inc.
PRAH
$566K 0.02%
+7,427
New +$561K
ESPR
117
DELISTED
Esperion Therapeutics
ESPR
$540K 0.02%
+10,769
New +$519K
IMGN
118
DELISTED
Immunogen Inc
IMGN
$536K 0.02%
+70,126
New +$466K
PRTK
119
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$532K 0.02%
+21,186
New +$493K
INOV
120
DELISTED
Inovalon Holdings, Inc. Class A Common Stock
INOV
$511K 0.02%
+30,000
New +$420K
CUTR
121
DELISTED
Cutera, Inc.
CUTR
$495K 0.02%
11,981
– –
TDOC icon
122
Teladoc Health
TDOC
$1.12B
$485K 0.02%
+14,641
New +$480K
KYNB
123
Kyntra Bio
KYNB
$32.8M
$462K 0.02%
+344
New +$362K
AKAO
124
DELISTED
Achaogen Inc
AKAO
$439K 0.02%
27,551
– –
NBRV
125
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$431K 0.02%
+210
New +$493K
3 4
5
6 7

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q3 2017 Portfolio in Review

As of Q3 2017, Perceptive Advisors held 172 positions worth $2.62B, up 32% from $1.99B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Perceptive Advisors deployed $217M of net new capital in Q3 2017, opening 46 new positions and adding to 29 existing holdings. Its largest new stake was Cymabay Therapeutics: 2,350,882 shares worth $18.9M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Industrials and Consumer Staples.

On the sell side, the largest reduction was Aravive, Inc. Common Stock, an estimated $42.4M trimmed.

  • Perceptive Advisors's largest Q3 2017 buy was Cymabay Therapeutics: 2,350,882 shares worth $18.9M.
  • Perceptive Advisors added most to Neurocrine Biosciences in Q3 2017, an estimated $64.1M increase.
  • Perceptive Advisors's biggest Q3 2017 reduction was Aravive, Inc. Common Stock, cutting an estimated $42.4M.
  • Perceptive Advisors fully exited Sarepta Therapeutics in Q3 2017, selling an estimated $36.7M.
  • Perceptive Advisors's ten largest holdings make up 54% of its $2.62B portfolio in Q3 2017.
  • Perceptive Advisors opened 46 new positions and closed 33 in Q3 2017.
  • Perceptive Advisors's portfolio value rose 32% quarter-over-quarter to $2.62B.

Based on Perceptive Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.